Noema Pharma: Biotech Company Closes Series B At About $147 Million
By Amit Chowdhry ● Dec 13, 2024
Noema Pharma - a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders - announced the closing of a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital raised in the round to CHF 130 million (about $147 million). With an investment in Noema Pharma, EQT Life Sciences joins the syndicate of previous Series B investors, including Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus, and UPMC Enterprises.